Sznajder, Łukasz J. https://orcid.org/0000-0001-6822-6485
Khan, Mahreen https://orcid.org/0000-0002-9900-978X
Ciesiołka, Adam https://orcid.org/0000-0003-3165-9791
Tadross, Mariam
Nutter, Curtis A.
Taylor, Katarzyna https://orcid.org/0000-0003-3219-6872
Pearson, Christopher E. https://orcid.org/0000-0001-9545-4205
Lewis, Mark H.
Hines, Rochelle M. https://orcid.org/0000-0002-0459-7911
Swanson, Maurice S. https://orcid.org/0000-0001-6245-5367
Sobczak, Krzysztof
Yuen, Ryan K. C. https://orcid.org/0000-0001-7273-4968
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R16GM154702)
Muscular Dystrophy Association (MDA546770)
Myotonic Dystrophy Foundation
University of Nevada, Las Vegas
University of Florida Center for Autism and Neurodevelopment Disorders
Narodowe Centrum Nauki (2020/39/D/NZ3/01658, 2020/38/A/NZ3/00498)
Gouvernement du Canada | Canadian Institutes of Health Research (FRN-148910, FRN-173282)
the Petroff Family Foundation Tribute Communities the Marigold Foundation Tier 1 Canada Research Chair in Disease-Associated Genome Instability
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (P50NS132955, R01NS103172, R15NS124008)
Azrieli Foundation
The Hospital for Sick Children’s Research Institute The University of Toronto McLaughlin Centre and Canadian Institutes of Health Research
Article History
Received: 31 July 2023
Accepted: 14 March 2025
First Online: 21 April 2025
Competing interests
: M.S.S. is a Scientific Advisory Board member of Skyhawk Therapeutics and Tacit Therapeutics. The other authors declare no competing interests.